
Diagnostics company developing host-response sepsis tests including SeptiCyte RAPID for hospital laboratories.
immunexpress.comCrawled Oct 16, 2026
In 447 suspected sepsis patients, SeptiCyte LAB predicted all patients with a positive blood culture in a matter of a few hours.
Immunexpress announced that data validating EDTA blood as a sample type for SeptiCyte RAPID were presented at the Association for Molecular Pathology 2022 Annual Meeting.
Westwood One reports that many people do not know what sepsis is. The page describes sepsis as body-wide inflammation triggered by the body's response to infection and mentions a potentially faster detection method.
Immunexpress reported that SeptiCyte RAPID assessed COVID-19 severity, that an elevated SeptiScore at hospital intake predicted ICU admission, and that the test outperformed routinely used single-biomarker assays.
The page discusses a rapid response test for sepsis with developer Richard Brandon. It describes sepsis as an immune response to infection that affects 750,000 Americans annually and can cause severe illness and organ damage.
Immunexpress Group announced a collaboration with the MARS Consortium to improve care for patients with sepsis.
Immunexpress Group received AUD $982,707 in Early Stage Commercialisation support through Commercialisation Australia to further develop SeptiCytePLUS.
Immunexpress Group announced the grant of an EU patent for a method of diagnosing herpes virus infection by monitoring changes in host gene expression after treatment.
Immunexpress Group announced a U.S. patent grant for a method of diagnosing herpes virus infection by monitoring changes in host gene expression after treatment.
Immunexpress CEO Rollie Carlson appeared on the Mastering Medical Device podcast. Carlson worked at Abbott Laboratories for 20 years, beginning in R&D and later holding leadership positions in global businesses and start-ups.
Immunexpress is a molecular diagnostic company committed to improving outcomes for suspected sepsis patients and healthcare providers.
The Immunexpress Privacy Policy, last updated November 20, 2018, identifies Immunexpress Inc. as responsible for processing personal information and describes how it collects, holds, and uses information about individuals.